HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ireland Sets Maximum Levels For Vitamins As Supplement Popularity Grows

Executive Summary

As more and more dietary supplements flood the Irish market to meet the demand created by the COVID-19 pandemic, Ireland has joined a number of its EU neighbors in setting maximum levels for certain vitamins and minerals to protect consumer health.

You may also be interested in...



Vitamin D Supplements And COVID-19: Still No Evidence, No Harm In Doing It Anyway

Two new RCTs cast further doubt on the preventative effects of vitamin D supplementation with regards to COVID-19 infection. Nevertheless, an editorial in the British Medical Journal, where the studies were published, leaves open positive effects for those suffering from vitamin D deficiency, and recommends a daily supplement of up to 2000IU just in case.

No OTC High Dose Vit D3 Supplements, Say German Doctors After Infant Overdose Case

The Drug Commission of the German Medical Association warns against the unsupervised use of high-dose vitamin D3 supplements after the overdose of a seven-month-old German infant.

Petition Suggests Rx-Only Vitamin B6 At 10-MG And Up In US, Add Warning To All Doses

Emery Pharma's citizen petition discusses potential health risks from vitamin B6 use, saying “there is a significant lack of data to justify supplementation in individuals with adequate B6 levels, entirely.”

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS150359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel